A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off

Leuk Lymphoma. 2024 Mar 5:1-4. doi: 10.1080/10428194.2024.2325188. Online ahead of print.

Marie Leroy¹, Laure Deramoudt^{1

2}, Marine Pinturaud^{1

2}, Julie Demaret^{3

4}, Enagnon Kazali Alidjinou⁵, Morgane Nudel⁶, Doriane Cavalieri⁶, Wadih Abou Chahla⁷, Pascal Odou^{1

2}, Franck Morschhauser^{2

6}, Ibrahim Yakoub-Agha^{4

6}, Nicolas Simon^{1

2}, David Beauvais^{6

8}

¹ CHU Lille, Institut de Pharmacie, Lille, France.
² Univ Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France.
³ CHU Lille, Institut d'Immunologie, Lille, France.
⁴ CHU de Lille, Université de Lille, INSERM Infinite U1285, Lille, France.
⁵ Virology Laboratory, ULR 3610, CHU Lille, University of Lille, Lille, France.
⁶ Hematology Department, CHU Lille, Lille, France.
⁷ Department of Pediatric Hematology, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France.
⁸ Univ Lille, Inserm U1192 - PRISM, Lille, France.

No abstract available